Oxiracetam
Also known as: ISF-2522
Racetam Nootropic | Logic, Processing Speed & Technical Work
Overview
Oxiracetam (ISF-2522) is a synthetic nootropic compound belonging to the racetam family, first developed in the 1970s by ICF, an Italian pharmaceutical company. It is a hydroxylated derivative of piracetam and is approved as a prescription medication in Italy and several other European and Asian countries for the treatment of cognitive decline associated with dementia and organic brain syndromes. Among the racetams, oxiracetam is widely regarded as the most effective for logical reasoning, mathematical thinking, and technical work -- a reputation that distinguishes it from piracetam, which users more commonly associate with verbal fluency and creative thinking. Oxiracetam is well absorbed orally with high bioavailability, is not significantly metabolized by the liver, and is excreted largely unchanged by the kidneys, giving it a clean pharmacokinetic profile with minimal drug-drug interaction potential.
Key benefits
- Enhanced logical reasoning, analytical thinking, and mathematical ability -- the cognitive domains where oxiracetam most clearly outperforms other racetams
- Improved processing speed and working memory capacity, facilitating technical work and complex problem-solving
- Mild psychostimulant effect that increases mental alertness without the jitteriness or crash associated with caffeine or amphetamines
- Strong safety profile with decades of clinical use in Europe and Asia, minimal hepatic metabolism, and low interaction potential
- Enhanced memory formation and consolidation through AMPA receptor modulation and increased hippocampal acetylcholine release
- Neuroprotective properties demonstrated in animal models of ischemia and excitotoxic injury
Mechanism of action
Oxiracetam enhances cognitive function primarily through positive allosteric modulation of AMPA-type glutamate receptors, increasing the excitatory postsynaptic response to glutamate and facilitating long-term potentiation (LTP) in hippocampal and cortical circuits. This AMPA modulation is thought to underlie its effects on memory encoding and retrieval. Additionally, oxiracetam stimulates cholinergic neurotransmission by increasing the release of acetylcholine in the hippocampus and cortex, which contributes to improvements in attention, working memory, and the speed of information processing. Unlike some stimulant nootropics, oxiracetam does not act on dopaminergic or serotonergic systems, which accounts for its low abuse potential and absence of mood-altering side effects. Oxiracetam also increases phospholipid metabolism in the brain, specifically the turnover of phosphatidylcholine and phosphatidylethanolamine, which may support membrane integrity and synaptic function. The compound increases D-aspartate release in the hippocampus, providing an additional pathway for NMDA receptor activation and synaptic plasticity. Its selectivity for logical and analytical cognition, as reported by users, may relate to preferential enhancement of cortical circuits involved in sequential reasoning and working memory manipulation, though this distinction has not been rigorously dissected in controlled studies.
Molecular data
- Type
- Racetam (C6H10N2O3), 4-hydroxy derivative of piracetam
- Half-life
- ~8 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Cognitive Enhancement
Clinical (Approved in Italy and Other Countries)
Investigational
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 800 mg | Twice daily (morning and early afternoon) | — |
| — | 400 mg | Twice daily (morning and early afternoon) | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Headache (the most frequently reported side effect, almost always caused by increased acetylcholine demand outstripping choline supply -- resolved by co-supplementing with Alpha-GPC or CDP-Choline)
- Insomnia or sleep disruption when taken too late in the day, due to the mild stimulant effect and 8-hour half-life
- Mild anxiety or nervousness, particularly in anxiety-prone individuals or at higher doses
- Mild gastrointestinal discomfort, nausea, or diarrhea (uncommon and usually transient)
Rare side effects
- Dizziness or lightheadedness
- Excessive stimulation or restlessness at high doses (above 2400 mg/day)
- Jaw tension or bruxism (reported anecdotally, mechanism unclear)
- Skin rash or hypersensitivity reaction
Contraindications
- Known hypersensitivity to oxiracetam or other racetam compounds
- Severe renal impairment (oxiracetam is excreted primarily by the kidneys unchanged)
- Pregnancy and breastfeeding (insufficient safety data)
- Epilepsy or seizure disorders (racetams may lower the seizure threshold in susceptible individuals, though this risk is considered low with oxiracetam)
Monitoring
- Subjective cognitive assessment: track logical reasoning, memory, and focus during the first 1-2 weeks to establish optimal dose
- Choline intake: if headaches develop, add or increase choline supplementation before reducing oxiracetam dose
- Sleep quality: monitor for insomnia and ensure the last dose is taken no later than early afternoon
- Renal function: periodic monitoring recommended for individuals with pre-existing kidney conditions, as the compound is renally cleared
References
Primary literature and clinical-trial data informing this entry.